American Lung Association’s ‘State of Lung Cancer’ report reveals stark differences in survival, screening and treatment across states ...

Lung cancer biomarkers may include genetic ... but tissue biopsy, surgery samples or serum/plasma samples are viable alternatives as well. Despite several advantages of the genomic-based ...

The lung cancer survival rate has improved 26% in the last five years, according to the American Lung Association’s ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

Biomarker coverage: Comprehensive biomarker testing is used by physicians to determine the most effective form of treatment for lung cancer, though insurance coverage for the testing varies by state.

The report also presents opportunities for states to further improve lung cancer survival by increasing access biomarker testing, and for the federal government to work to increase access to ...

But a lot of work remains to get eligible people screened for lung cancer and expand affordable access to the targeted treatments that can be accomplished with biomarker testing. Close to 235,000 ...